\begin{longtable}{p{0.2\textwidth}p{0.13\textwidth}p{0.13\textwidth}p{0.13\textwidth}p{0.13\textwidth}p{0.13\textwidth}p{0.14\textwidth}}
   & Semaglutide & Dulaglutide & Liraglutide & Tirzepatide & Other & Overall \\ 
  \hline 
\endfirsthead 
\multicolumn{7}{p{\textwidth}}{{ \bfseries \tablename \thetable{} -- continued from previous page}} \ 
\hline Feature & Semaglutide & Dulaglutide & Liraglutide & Tirzepatide & Other & Overall \\ \hline 
\endhead 
\hline \multicolumn{7}{p{\textwidth}}{{Continued on next page}} \\ \hline 
\endfoot 
\hline 
\endlastfoot 
 \hline
 & (N=79189) & (N=16403) & (N=7610) & (N=14110) & (N=650) & (N=117962) \\ 
  Age &  &  &  &  &  &  \\ 
    Mean (SD) & 55 (14) & 60 (13) & 49 (14) & 52 (13) & 65 (14) & 55 (14) \\ 
  Age Group &  &  &  &  &  &  \\ 
    0-17 & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    18-44 & 19485 (25\%) & 2200 (13\%) & 2921 (38\%) & 4069 (29\%) & 58 (9\%) & 28733 (24\%) \\ 
    45-64 & 39919 (50\%) & 7937 (48\%) & 3673 (48\%) & 7653 (54\%) & 237 (36\%) & 59419 (50\%) \\ 
    65+ & 19785 (25\%) & 6266 (38\%) & 1016 (13\%) & 2388 (17\%) & 355 (55\%) & 29810 (25\%) \\ 
  Sex &  &  &  &  &  &  \\ 
    Female & 55400 (70\%) & 9339 (57\%) & 6176 (81\%) & 10100 (72\%) & 346 (53\%) & 81361 (69\%) \\ 
    Male & 23748 (30\%) & 7054 (43\%) & 1428 (19\%) & 4003 (28\%) & 303 (47\%) & 36536 (31\%) \\ 
    Unknown & 41 (0\%) & 10 (0\%) & 6 (0\%) & 7 (0\%) & 1 (0\%) & 65 (0\%) \\ 
  Race &  &  &  &  &  &  \\ 
    White & 56761 (72\%) & 11015 (67\%) & 5322 (70\%) & 10660 (76\%) & 460 (71\%) & 84218 (71\%) \\ 
    Black & 12508 (16\%) & 3061 (19\%) & 1446 (19\%) & 1811 (13\%) & 103 (16\%) & 18929 (16\%) \\ 
    Asian & 2007 (3\%) & 495 (3\%) & 110 (1\%) & 211 (1\%) & 14 (2\%) & 2837 (2\%) \\ 
    AI or AN & 530 (1\%) & 126 (1\%) & 76 (1\%) & 82 (1\%) & 7 (1\%) & 821 (1\%) \\ 
    NH or PI & 359 (0\%) & 89 (1\%) & 36 (0\%) & 37 (0\%) & 4 (1\%) & 525 (0\%) \\ 
    Other Race & 4187 (5\%) & 993 (6\%) & 398 (5\%) & 866 (6\%) & 32 (5\%) & 6476 (5\%) \\ 
    Declined to answer & 726 (1\%) & 144 (1\%) & 44 (1\%) & 108 (1\%) & 4 (1\%) & 1026 (1\%) \\ 
    Unknown & 2111 (3\%) & 480 (3\%) & 178 (2\%) & 335 (2\%) & 26 (4\%) & 3130 (3\%) \\ 
  Ethnicity &  &  &  &  &  &  \\ 
    Hispanic or Latino & 8272 (10\%) & 2014 (12\%) & 820 (11\%) & 1607 (11\%) & 64 (10\%) & 12777 (11\%) \\ 
    Not Hispanic or Latino & 67103 (85\%) & 13508 (82\%) & 6479 (85\%) & 11837 (84\%) & 543 (84\%) & 99470 (84\%) \\ 
    Declined to answer & 955 (1\%) & 196 (1\%) & 64 (1\%) & 134 (1\%) & 7 (1\%) & 1356 (1\%) \\ 
    Unknown & 2859 (4\%) & 685 (4\%) & 247 (3\%) & 532 (4\%) & 36 (6\%) & 4359 (4\%) \\ 
  T2D & 38701 (49\%) & 14066 (86\%) & 2200 (29\%) & 6677 (47\%) & 559 (86\%) & 62203 (53\%) \\ 
  Obesity or Overweight & 71431 (90\%) & 13812 (84\%) & 7113 (93\%) & 12589 (89\%) & 489 (75\%) & 105434 (89\%) \\ 
  FDA-labeled Use &  &  &  &  &  &  \\ 
    T2D & 37728 (48\%) & 16403 (100\%) & 1579 (21\%) & 14110 (100\%) & 650 (100\%) & 70470 (60\%) \\ 
    Obesity & 14738 (19\%) & 0 (0\%) & 2628 (35\%) & 0 (0\%) & 0 (0\%) & 17366 (15\%) \\ 
    Unknown & 26723 (34\%) & 0 (0\%) & 3403 (45\%) & 0 (0\%) & 0 (0\%) & 30126 (26\%) \\ 
  Brand &  &  &  &  &  &  \\ 
    Ozempic & 28500 (36\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 28500 (24\%) \\ 
    Rybelsus & 7674 (10\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 7674 (7\%) \\ 
    Wegovy & 14738 (19\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 14738 (12\%) \\ 
    Trulicity & 0 (0\%) & 16403 (100\%) & 0 (0\%) & 0 (0\%) & 1 (0\%) & 16404 (14\%) \\ 
    Victoza & 0 (0\%) & 0 (0\%) & 1579 (21\%) & 0 (0\%) & 0 (0\%) & 1579 (1\%) \\ 
    Saxenda & 0 (0\%) & 0 (0\%) & 2628 (35\%) & 0 (0\%) & 0 (0\%) & 2628 (2\%) \\ 
    Mounjaro & 0 (0\%) & 0 (0\%) & 0 (0\%) & 14110 (100\%) & 0 (0\%) & 14110 (12\%) \\ 
    Bydureon & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 203 (31\%) & 203 (0\%) \\ 
    Byetta & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 27 (4\%) & 27 (0\%) \\ 
    Soliqua & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 333 (51\%) & 333 (0\%) \\ 
    Unknown & 28277 (36\%) & 0 (0\%) & 3403 (45\%) & 0 (0\%) & 86 (13\%) & 31766 (27\%) \\ 
  Period &  &  &  &  &  &  \\ 
    2018 Jan-Jun & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    2018 Jul-Dec & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    2019 Jan-Jun & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    2019 Jul-Dec & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    2020 Jan-Jun & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    2020 Jul-Dec & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    2021 Jan-Jun & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    2021 Jul-Dec & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    2022 Jan-Jun & 4377 (6\%) & 1471 (9\%) & 682 (9\%) & 96 (1\%) & 66 (10\%) & 6692 (6\%) \\ 
    2022 Jul-Dec & 25759 (33\%) & 7980 (49\%) & 4126 (54\%) & 6531 (46\%) & 305 (47\%) & 44701 (38\%) \\ 
    2023 Jan-Jun & 49053 (62\%) & 6952 (42\%) & 2802 (37\%) & 7483 (53\%) & 279 (43\%) & 66569 (56\%) \\ 
    2023 Jul-Dec & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
  Atrial Fibrilation & 5047 (6\%) & 1514 (9\%) & 355 (5\%) & 710 (5\%) & 78 (12\%) & 7704 (7\%) \\ 
  Asthma & 16162 (20\%) & 3111 (19\%) & 1828 (24\%) & 2804 (20\%) & 99 (15\%) & 24004 (20\%) \\ 
  CKD & 9489 (12\%) & 3448 (21\%) & 723 (10\%) & 1223 (9\%) & 164 (25\%) & 15047 (13\%) \\ 
  COPD & 5353 (7\%) & 1828 (11\%) & 483 (6\%) & 721 (5\%) & 78 (12\%) & 8463 (7\%) \\ 
  Glaucoma & 1713 (2\%) & 534 (3\%) & 114 (1\%) & 202 (1\%) & 31 (5\%) & 2594 (2\%) \\ 
  Heart Failure & 5649 (7\%) & 2058 (13\%) & 451 (6\%) & 711 (5\%) & 98 (15\%) & 8967 (8\%) \\ 
  Hyperlipidemia & 51155 (65\%) & 12529 (76\%) & 3798 (50\%) & 8472 (60\%) & 496 (76\%) & 76450 (65\%) \\ 
  Hypertension & 50813 (64\%) & 12875 (78\%) & 4105 (54\%) & 8582 (61\%) & 505 (78\%) & 76880 (65\%) \\ 
  Ischemic Heart Disease & 5222 (7\%) & 1931 (12\%) & 384 (5\%) & 746 (5\%) & 85 (13\%) & 8368 (7\%) \\ 
  Acute MI & 2188 (3\%) & 828 (5\%) & 172 (2\%) & 293 (2\%) & 40 (6\%) & 3521 (3\%) \\ 
  Ischemic Stroke & 187 (0\%) & 72 (0\%) & 19 (0\%) & 29 (0\%) & 4 (1\%) & 311 (0\%) \\ 
  Major Depressive Disorder & 17965 (23\%) & 3371 (21\%) & 2100 (28\%) & 2994 (21\%) & 122 (19\%) & 26552 (23\%) \\ 
  Osteoporosis & 2821 (4\%) & 732 (4\%) & 195 (3\%) & 363 (3\%) & 28 (4\%) & 4139 (4\%) \\ 
  Bariatric Surgery & 2760 (3\%) & 297 (2\%) & 500 (7\%) & 504 (4\%) & 8 (1\%) & 4069 (3\%) \\ 
  Metformin & 30922 (39\%) & 10206 (62\%) & 1718 (23\%) & 5400 (38\%) & 380 (58\%) & 48626 (41\%) \\ 
  SGLT2i & 10633 (13\%) & 4363 (27\%) & 493 (6\%) & 1690 (12\%) & 193 (30\%) & 17372 (15\%) \\ 
  DPP4 & 5678 (7\%) & 2743 (17\%) & 197 (3\%) & 847 (6\%) & 91 (14\%) & 9556 (8\%) \\ 
  Sulfonylurea & 10075 (13\%) & 4652 (28\%) & 393 (5\%) & 1413 (10\%) & 185 (28\%) & 16718 (14\%) \\ 
  Insulin & 5265 (7\%) & 2111 (13\%) & 662 (9\%) & 759 (5\%) & 96 (15\%) & 8893 (8\%) \\ 
  Orlistat & 146 (0\%) & 14 (0\%) & 38 (0\%) & 16 (0\%) & 1 (0\%) & 215 (0\%) \\ 
  Phentermine Topiramate & 483 (1\%) & 11 (0\%) & 70 (1\%) & 112 (1\%) & 0 (0\%) & 676 (1\%) \\ 
  BMI &  &  &  &  &  &  \\ 
    Mean (SD) & 38 (8.4) & 36 (8.5) & 40 (9.1) & 38 (8.4) & 35 (8.8) & 38 (8.5) \\ 
    Missing & 33342 (42.1\%) & 7057 (43.0\%) & 3408 (44.8\%) & 6977 (49.4\%) & 375 (57.7\%) & 51159 (43.4\%) \\ 
  Weight (in lbs) &  &  &  &  &  &  \\ 
    Mean (SD) & 230 (54) & 220 (57) & 240 (58) & 240 (56) & 210 (55) & 230 (55) \\ 
    Missing & 20676 (26.1\%) & 3536 (21.6\%) & 2227 (29.3\%) & 3604 (25.5\%) & 160 (24.6\%) & 30203 (25.6\%) \\ 
  HbA1c &  &  &  &  &  &  \\ 
    Mean (SD) & 7.0 (1.7) & 8.2 (1.9) & 6.3 (1.5) & 6.8 (1.6) & 8.7 (1.9) & 7.1 (1.8) \\ 
    Missing & 27427 (34.6\%) & 4390 (26.8\%) & 3520 (46.3\%) & 5270 (37.3\%) & 236 (36.3\%) & 40843 (34.6\%) \\ 
  \hline
\caption{Characteristics of patients first prescribed a GLP-1 RA in May 2022 or later, by specific medication Other includes the two smallest groups: Exenatide and Lixisenatide.\Abbreviations: 
ADM=anti-diabetic medication,
AI  = American Indian, 
AN = Alaska Native, 
AOM=anti-obesity medication, 
Black = Black or African American, 
BMI = body mass index,
CKD=chronic kidney disease, 
COPD=chronic obstructive pulmonary disease, 
DPP4= dipeptidyl peptidase 4 inhibitor, 
FDA=Food and Drug Administration, 
HbA1c=hemoglobin A1C, 
MI=myocardial infarction, 
NH = Native Hawaiian, 
PI = Pacific Islander, 
SD=standard deviation, 
SGLT2i=sodium/glucose cotransporter-2 inhibitor,
T2D=type 2 diabetes mellitus.} 
\label{tab:table_1_generic_postMay22}
\end{longtable}
